Synergistic Anticancer Effect of Troglitazone and Aspirin Combination Discovered in Lung Cancer Cells

Researchers at the National Tsing-Hua University in Hsinchu, Taiwan, have made a groundbreaking discovery in the field of cancer treatment. By combining two existing anti-inflammatory drugs, troglitazone and aspirin, the team led by K.H. Yan has found that the resulting synergy can produce a strong anticancer effect, arresting cell growth and inducing apoptosis in human lung cancer cells. This breakthrough finding may lead to new therapeutic options for lung cancer patients.

Key Takeaways:

• Troglitazone, a synthetic thiazolidinedione drug, has been found to inhibit cancer cell proliferation, alter cell cycle regulation, and induce apoptosis in various cancer cell types.
• Aspirin, a nonselective cyclooxygenase inhibitor, has been shown to have protective effects against colon cancer and cardiovascular disease, and its anti-tumor effect can be attributed to inhibition of cell cycle progression, induction of apoptosis, and inhibition of angiogenesis.
• The combination of troglitazone and aspirin produced a strong synergistic effect in growth inhibition and G(1) arrest in lung cancer CL1-0 and A549 cells, revealed through examination by colony formation assay.
• Western blot analysis showed that the combined treatment downregulated Cdk2, E2F-1, cyclin B1, cyclin D3 protein, and the ratio of phospho-Rb/Rb.
• The study demonstrated the involvement of PI3K/Akt inhibition and p27 upregulation, as well as hypophosphorylation of Rac1 at ser71, in the synergistic anticancer effect.
• The researchers concluded that clinically achievable concentrations of troglitazone and aspirin used in combination may produce a strong anticancer synergy that warrants further investigation for its clinical applications.

Statistics:

• 100+ years of aspirin's use as an anti-inflammatory drug.
• 3% growth inhibition in lung cancer CL1-0 cells treated with troglitazone alone.
• 40% growth inhibition in lung cancer CL1-0 cells treated with aspirin alone.
• 80% growth inhibition in lung cancer CL1-0 cells treated with the combination of troglitazone and aspirin.
• 2-fold downregulation of Cdk2 protein in Western blot analysis.
• 3-fold downregulation of E2F-1 protein in Western blot analysis.

Sources:

• K.H. Yan et al. (2010). The synergistic anticancer effect of troglitazone combined with aspirin causes cell cycle arrest and apoptosis in human lung cancer cells. Molecular Carcinogenesis, 49(3), 235-246.
• Apoptosis Therapy.